Phase I Studies of Vorinostat With Ixazomib or Pazopanib Imply a Role of Antiangiogenesis-Based Therapy for TP53 Mutant Malignancies
Scientific Reports - United Kingdom
doi 10.1038/s41598-020-58366-z
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 20, 2020
Authors
Publisher
Springer Science and Business Media LLC